10-K: SAB Biotherapeutics Outlines Share Structure and Pipeline in 10-K Filing

SAB Biotherapeutics details its registered securities, including common stock and warrants, and provides an overview of its clinical-stage pipeline in its latest 10-K filing.

Summary

• SAB Biotherapeutics has two classes of registered securities: common stock and warrants, with each warrant exercisable for one share of common stock at $115.00.
• The company's authorized capital stock consists of 800,000,000 shares of common stock and 10,000,000 shares of preferred stock.
• Holders of common stock are entitled to one vote per share and to receive dividends as declared by the board of directors.
• The warrants expire five years after the completion of the merger, or earlier upon redemption or liquidation.
• The company is focused on developing human polyclonal immunotherapeutic antibodies for immune system disorders and infectious diseases.
• Their lead candidate, SAB-142, is a human anti-thymocyte globulin (ATG) for preventing or delaying the progression of type 1 diabetes (T1D).
• A Phase 1 trial of SAB-142 has been initiated to establish its safety and pharmacokinetic profiles.
• SAB-176, an immunoglobulin targeting multiple strains of influenza, has received Fast Track and Breakthrough Therapy designations from the FDA.
• The company's DiversitAb platform is used to generate novel therapeutic candidates, producing disease-targeted hIgG in large quantities without human plasma donors.
• The company has completed multiple clinical trials, including Phase 1, Phase 2 and Phase 3, with over 700 individuals dosed with their proprietary hIgGs.
• The company has secured up to $110 million in gross proceeds to advance SAB-142 to Phase 2 results by 2026.
• The company has completed GLP toxicity studies for SAB-142 and initiated a GLP juvenile toxicity study to enable Phase 2b clinical trials in adolescent patients.
• The company has established proof-of-concept for its DiversitAb production system and CMC for multiple disease indications.
• The company has demonstrated a safety profile in >700 patients of hIgG produced in the DiversitAb production system.
• The company has demonstrated proof of clinical concept for its DiversitAb production system across seven clinical trials from Phase 1 to Phase 3 across treatment of three indications (MERS, Influenza, and COVID-19).
• The company's unique production system harnesses the natural advantages of polyclonal immunoglobulins to protect against evolving disease targets.
• The company's regulatory pathway has been established with the US FDA, MHRA in the United Kingdom, and TGA in Australia.
• The company's polyclonal development approach leverages its production system to capture discovery and production efficiencies not available to mAb product development.
• The company's discovery process involves antigen design and production, with the vaccinated Tc Bovine performing antibody design, down selection, and scaled production.
• The company's Phase 1 trial for SAB-142 commenced dosing in healthy volunteers in November 2023.
• The company anticipates topline results from the Phase 1 trial by the end of 2024.
• The company plans to file a clinical trial application (CTA) in the EU and an investigational new drug (IND) application in the United States to expand the clinical trials to global jurisdictions.
• The company has completed multiple clinical and nonclinical studies for SAB-176, including a Phase 2a challenge study that showed a significant reduction in patient pH1N1 influenza viral load.
• The company operates two plasma fractionation purification facilities in Sioux Falls, South Dakota, with a 50L small batch scale cGMP suite and a 200L scale larger batch cGMP suite.
• The company has fully GLP and cGMP compliant quality control testing facilities and has developed its own internal antigen (immunogen) discovery and production capabilities.
• The company's Tc Bovine are housed at dedicated specialty facilities accredited by the AAALAC.
• The company's patent portfolio includes over 40 issued patents or pending applications, with global patent protection expected to extend to 2041 and beyond.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has promising technology and a pipeline, it faces significant financial challenges and risks associated with drug development and regulatory approvals. The decrease in revenue and increase in net loss are concerning, but the company has secured funding and is advancing its clinical programs.

Positives

• The company has a strong pipeline with multiple clinical-stage assets.
• The company's DiversitAb platform offers a unique approach to antibody production.
• The company has a demonstrated regulatory pathway with multiple agencies.
• The company has a strong safety profile with over 700 patients dosed with their hIgG therapeutics.
• The company has secured significant funding to advance its lead program.
• The company has a rapid product development capability.
• The company has a multivalent product platform to address complex diseases.
• The company has a strong intellectual property portfolio.

Negatives

• The company has incurred significant losses since its inception.
• The company's product candidates are in early stages of development and require substantial additional investment.
• The company is dependent on third parties for manufacturing and clinical trials.
• The company's success is highly dependent on the success of its product candidates.
• The company may face difficulties enrolling patients in clinical trials.
• The company's product candidates may cause undesirable side effects.
• The company may not be able to obtain regulatory approval for its product candidates.
• The company may not be able to commercialize its product candidates successfully.

Risks

• The company is a clinical-stage biopharmaceutical company and has incurred significant losses since its inception.
• The successful development of pharmaceutical products is highly uncertain.
• All of the company's product candidates are in preclinical or clinical development.
• Regulatory approval for the genetic modification of animals requires the approval of a New Animal Drug Application, which can be a lengthy and expensive process.
• If the company encounters difficulties enrolling patients in clinical trials, clinical trials of its product candidates may be delayed or otherwise adversely affected.
• The company's business is highly dependent on the success of its product candidates.
• The regulatory approval processes of the FDA are lengthy, time-consuming and inherently unpredictable.
• The company may never obtain FDA approval for any product candidates in the United States.
• If the company's clinical trials fail to replicate positive results from earlier preclinical studies or clinical trials, the company may be unable to successfully develop, obtain regulatory approval for or commercialize its product candidates.
• The company's product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval.
• The company depends upon senior management and senior scientific staff, and their loss or unavailability could put the company at a competitive disadvantage.
• The company relies on third parties to perform some of its research and preclinical studies, and plans to rely on third parties to conduct its clinical trials.
• The company intends to rely on third parties to produce commercial supplies of its product candidates.
• If the company fails to successfully operate its animal production facility, it may adversely affect its clinical trials and the commercial viability of its product candidates.
• The company has not entered into long term manufacturing and supply agreements with any producers.
• Cyber-attacks or other failures in the company's telecommunications or information technology systems could result in information theft, data corruption and significant disruption of the company's business operations.
• The company is subject to stringent environmental regulation and potentially subject to environmental litigation, proceedings, and investigations.
• The company's success may depend on its ability to maintain the proprietary nature of its technology.
• The company may become involved in litigation to protect or enforce its patents or the patents of its collaborators or licensors, which could be expensive and time-consuming.
• If patent laws or the interpretation of patent laws change, the company's competitors may be able to develop and commercialize its discoveries.
• The company has third party collaborators that might claim rights in or to its technology and/or assets.
• The company incurs increased costs and demands upon management as a result of complying with the laws and regulations affecting public companies.
• If the company fails to maintain an effective system of disclosure controls and internal control over financial reporting, its ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired.
• The company has identified a material weakness in its internal control over financial reporting and determined that its disclosure controls and procedures were ineffective as of December 31, 2023.
• The company's warrants are accounted for as liabilities and changes in value of the warrants could have a material effect on its financial results.
• The market price of the company's securities may be volatile.
• An investment in the company's common stock is extremely speculative and there can be no assurance of any return on any such investment.
• There can be no assurance that the company will be able to comply with the continued listing standards of Nasdaq.
• Future sales and issuances of the company's common stock or rights to purchase common stock could result in additional dilution of the percentage ownership of its stockholders and could cause its stock price to fall.
• The company has a significant number of warrants and shares of preferred stock convertible into shares of common stock, and the exercise or conversion thereof would increase the number of shares eligible for future resale in the public market and result in dilution to its stockholders.
• The company may be subject to securities litigation, which is expensive and could divert management attention.
• Changes in legislation in U.S. and foreign taxation of international business activities or the adoption of other tax reform policies, as well as the application of such laws, could adversely impact the company's financial position and operating results.

Future Outlook

The company expects to continue to incur significant expenses and losses as it continues the development of, and seeks regulatory approvals for, its product candidates, and begins commercialization of its products. The company also expects to continue to make significant investments in research and development efforts towards deepening its technology and expertise with its platform and as well as indications in infectious disease and autoimmune indications.

Management Comments

• The company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases with significant unmet medical needs, including immune and autoimmune disorders including T1D.
• The company is leveraging its proprietary production system to advance a robust pipeline of differentiated hIgG-based therapies for the treatment of immune system disorders and infectious diseases.
• The company's business strategy is focused on SAB-142 as a first-in-class, human, multi-target antibody treatment designed to provide superior efficacy and safety in delaying the onset or progression of T1D.
• The company's production system (DiversitAb TM) represents the first technology of its kind to produce large-scale human high-titer and high-avidity antibodies across multiple modalities.
• The company has a demonstrated regulatory pathway through each of the U.S. Food and Drug Administration (the FDA), CBER, UK Medicines and Healthcare products Regulatory Agency (MHRA), and Australian Therapeutic Goods Administration (TGA).
• The company's hIgGs have been safely demonstrated up through Phase 3 clinical trials with a patient safety database that includes over 700 patients who were safely administered our hIgG therapeutics.

Industry Context

This announcement highlights SAB Biotherapeutics' efforts to advance its pipeline of immunotherapeutic antibodies, which aligns with the broader industry trend of developing novel treatments for immune system disorders and infectious diseases. The company's focus on polyclonal antibodies and its proprietary production platform differentiate it from competitors primarily focused on monoclonal antibodies.

Comparison to Industry Standards

• SAB Biotherapeutics' approach to producing human polyclonal antibodies using transchromosomic cattle is a unique method compared to traditional methods that rely on human plasma donors, setting it apart from companies like CSL Behring and Grifols.
• The company's lead candidate, SAB-142, targets T1D using a polyclonal approach, which differs from the monoclonal antibody approach of teplizumab (Tzield) by Sanofi, offering a potentially more comprehensive immune modulation.
• The company's SAB-176, a multivalent anti-influenza immunoglobulin, aims to provide broader protection against diverse influenza strains, contrasting with the more targeted approach of small molecule antivirals like oseltamivir (Tamiflu) by Roche.
• The company's DiversitAb platform, which allows for rapid production of antibodies, contrasts with the more time-consuming processes of traditional antibody development, potentially giving it a competitive edge in responding to emerging infectious diseases.
• The company's focus on a multi-target approach with SAB-142 is similar to the mechanism of action of rabbit ATG (Thymoglobulin), but SAB-142 is human-derived, potentially reducing the risk of serum sickness and anti-drug antibodies.
• The company's manufacturing strategy, with its own cGMP facilities, is similar to other biopharmaceutical companies, but its use of transgenic cattle for antibody production is a unique approach.
• The company's intellectual property portfolio, with patents extending to 2041 and beyond, is comparable to other companies in the biotechnology space, but its specific focus on ungulate-derived human immunoglobulins is a differentiator.

Management Changes

Stakeholder Impact

• Shareholders face risks associated with the company's financial performance and the volatility of its stock price.
• Employees may be affected by potential changes in headcount or compensation due to the company's financial situation.
• Customers and partners may be impacted by the company's ability to successfully develop and commercialize its products.
• Suppliers and creditors may be affected by the company's ability to meet its financial obligations.

Next Steps

• The company plans to file a clinical trial application (CTA) in the EU and an investigational new drug (IND) application in the United States to expand the clinical trials to global jurisdictions.
• The company anticipates topline results from the Phase 1 trial for SAB-142 by the end of 2024.
• The company plans to bring the SAB-142 program to IND and CTA filings with global regulatory authorities by the mid-2024.
• The company plans to work with global health authorities and file clinical trial applications and clinical trial notifications in other countries to have a global footprint and reach patients with T1D worldwide.
• The company plans to progress into clinical trials in Stage 2 patients, those who do not yet have a full clinical onset of T1D.
• The company plans to evaluate the re-dosing of SAB-142 potentially aimed at fully preventing clinical onset of disease.

Key Dates

Keywords

Biotherapeutics, Immunotherapy, Polyclonal Antibodies, Type 1 Diabetes, Influenza, DiversitAb, hIgG, Clinical Trials, FDA, Warrants, Common Stock, ATG, Tc Bovine, Manufacturing, Regulatory